Hepatic fibrosis-Overview

Toxicology

Volumn 254, Issue 3, 2008, Pages 120-129

  Friedman, Scott L ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Anti fibrotic; Cirrhosis; Extracellular matrix; Hepatic fibrosis; Stellate cell

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA INTERFERON; ALPHA TOCOPHEROL; ANTIFIBROTIC AGENT; BOSENTAN; COLCHICINE; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLIOTOXIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMATINIB; LUFIRONIL; PENTOXIFYLLINE; PERFENIDONE; RAPAMYCIN; RELAXIN; SCATTER FACTOR; SILYMARIN; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

CELL ACTIVATION; CELL PROLIFERATION; CHEMOTAXIS; CHRONIC DISEASE; CLINICAL TRIAL; DISEASE COURSE; DRUG MECHANISM; FIBROGENESIS; GENOTYPE; HEPATITIS C; HUMAN; IMMUNOMODULATION; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; LIVER REGENERATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

ANIMALS; DISEASE PROGRESSION; HEPATIC STELLATE CELLS; HUMANS; LIVER CIRRHOSIS; LIVER REGENERATION; POLYMORPHISM, GENETIC;

EID: 56349107309     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2008.06.013     Document Type: Review

References (187)

1. Anan A., Baskin-Bey E.S., Bronk S.F., Werneburg N.W., Shah V.H., and Gores G.J. Proteasome inhibition induces hepatic stellate cell apoptosis. Hepatology 43 (2006) 335-344
2. Arii S., Mise M., Harada T., Furutani M., Ishigami S., Niwano M., Mizumoto M., Fukumoto M., and Imamura M. Overexpression of matrix metalloproteinase 9 gene in hepatocellular carcinoma with invasive potential. Hepatology 24 (1996) 316-322
3. Arthur M.J. Collagenases and liver fibrosis. J. Hepatol. 22 (1995) 43-48
4. Arthur M.J. Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol. 279 (2000) G245-G249
5. Arthur M.J., Stanley A., Iredale J.P., Rafferty J.A., Hembry R.M., and Friedman S.L. Secretion of 72 kDa type IV collagenase/gelatinase by cultured human lipocytes. Analysis of gene expression, protein synthesis and proteinase activity. Biochem. J. 287 (1992) 701-707
6. Bachem M.G., Melchior R., and Gressner A.M. The role of thrombocytes in liver fibrogenesis: effects of platelet lysate and thrombocyte-derived growth factors on the mitogenic activity and glycosaminoglycan synthesis of cultured rat liver fat storing cells. J. Clin. Chem. Clin. Biochem. 27 (1989) 555-565
7. Baroni G.S., Pastorelli A., Manzin A., Benedetti A., Marucci L., Solforosi L., Di Sario A., Brunelli E., Orlandi F., Clementi M., and Macarri G. Hepatic stellate cell activation and liver fibrosis are associated with necroinflammatory injury and Th1-like response in chronic hepatitis C. Liver 19 (1999) 212-219
8. Bataller R., North K.E., and Brenner D.A. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology 37 (2003) 493-503
9. Benhamou Y., Di Martino V., Bochet M., Colombet G., Thibault V., Liou A., Katlama C., and Poynard T. Factors affecting liver fibrosis in human immunodeficiency virus- and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 34 (2001) 283-287
10. Bennett R.G., Mahan K.J., Gentry-Nielsen M.J., and Tuma D.J. Relaxin receptor expression in hepatic stellate cells and in cirrhotic rat liver tissue. Ann. N. Y. Acad. Sci. 1041 (2005) 185-189
11. Beno D.W., Mullen J., and Davis B.H. Lipoxygenase inhibitors block PDGF-induced mitogenesis: a MAPK-independent mechanism that blocks fos and egr. Am. J. Physiol. 268 (1995) C604-610
12. Benyon R.C., and Arthur M.J. Extracellular matrix degradation and the role of hepatic stellate cells. Semin. Liver Dis. 21 (2001) 373-384
13. Benyon R.C., Iredale J.P., Goddard S., Winwood P.J., and Arthur M.J. Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver. Gastroenterology 110 (1996) 821-831
14. Bilzer M., Roggel F., and Gerbes A.L. Role of Kupffer cells in host defense and liver disease. Liver Int. 26 (2006) 1175-1186
15. Bonacchi A., Romagnani P., Romanelli R.G., Efsen E., Annunziato F., Lasagni L., Francalanci M., Serio M., Laffi G., Pinzani M., Gentilini P., and Marra F. Signal transduction by the chemokine receptor CXCR3: activation of Ras/ERK, Src, and phosphatidylinositol 3-kinase/Akt controls cell migration and proliferation in human vascular pericytes. J. Biol. Chem. 276 (2001) 9945-9954
16. Borkham-Kamphorst E., Stoll D., Gressner A.M., and Weiskirchen R. Antisense strategy against PDGF B-chain proves effective in preventing experimental liver fibrogenesis. Biochem. Biophys. Res. Commun. 321 (2004) 413-423
17. Borkham-Kamphorst E., Van Roeyen C.R., Ostendorf T., Floege J., Gressner A.M., and Weiskirchen R. Pro-fibrogenic potential of PDGF-D in liver fibrosis. J. Hepatol. 46 (2007) 1064-1074
18. Breitkopf K., Godoy P., Ciuclan L., Singer M.V., and Dooley S. TGF-beta/Smad signaling in the injured liver. Z. Gastroenterol. 44 (2006) 57-66
19. Brigstock D.R. The CCN family: a new stimulus package. J. Endocrinol. 178 (2003) 169-175
20. Brown K.E., Poulos J.E., Li L., Soweid A.M., Ramm G.A., O'neill R., Britton R.S., and Bacon B.R. Effect of vitamin E supplementation on hepatic fibrogenesis in chronic dietary iron overload. Am. J. Physiol. 272 (1997) G116-G123
21. Canbay A., Feldstein A.E., Higuchi H., Werneburg N., Grambihler A., Bronk S.F., and Gores G.J. Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology 38 (2003) 1188-1198
22. Canbay A., Friedman S., and Gores G.J. Apoptosis: the nexus of liver injury and fibrosis. Hepatology 39 (2004) 273-278
23. Canbay A., Higuchi H., Bronk S.F., Taniai M., Sebo T.J., and Gores G.J. Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology 123 (2002) 1323-1330
24. Canbay A., Taimr P., Torok N., Higuchi H., Friedman S., and Gores G.J. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab. Invest. 83 (2003) 655-663
25. Cortez-Pinto H., Alexandrino P., Camilo M.E., Gouveia-Oliveira A., Santos P.M., Alves M.M., and Moura M.C. Lack of effect of colchicine in alcoholic cirrhosis: final results of a double blind randomized trial. Eur. J. Gastroenterol. Hepatol. 14 (2002) 377-381
26. Czaja A.J., and Carpenter H.A. Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis. Hepatology 39 (2004) 1631-1638
27. D'amico G., Garcia-Tsao G., and Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J. Hepatol. 44 (2006) 217-231
28. Degott C., Zafrani E.S., Callard P., Balkau B., Poupon R.E., and Poupon R. Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression. Hepatology 29 (1999) 1007-1012
29. Dehmlow C., Erhard J., and De Groot H. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology 23 (1996) 749-754
30. Dekel R., Zvibel I., Brill S., Brazovsky E., Halpern Z., and Oren R. Gliotoxin ameliorates development of fibrosis and cirrhosis in a thioacetamide rat model. Dig. Dis. Sci. 48 (2003) 1642-1647
31. Demetri G.D., Von Mehren M., Blanke C.D., Van Den Abbeele A.D., Eisenberg B., Roberts P.J., Heinrich M.C., Tuveson D.A., Singer S., Janicek M., Fletcher J.A., Silverman S.G., Silberman S.L., Capdeville R., Kiese B., Peng B., Dimitrijevic S., Druker B.J., Corless C., Fletcher C.D., and Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347 (2002) 472-480
32. Di Sario A., Bendia E., Svegliati Baroni G., Ridolfi F., Casini A., Ceni E., Saccomanno S., Marzioni M., Trozzi L., Sterpetti P., Taffetani S., and Benedetti A. Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production. J. Hepatol. 37 (2002) 584-591
33. Di Sario A., Bendia E., Taffetani S., Marzioni M., Candelaresi C., Pigini P., Schindler U., Kleemann H.W., Trozzi L., Macarri G., and Benedetti A. Selective Na+/H+ exchange inhibition by cariporide reduces liver fibrosis in the rat. Hepatology 37 (2003) 256-266
34. Ding X., Saxena N.K., Lin S., Xu A., Srinivasan S., and Anania F.A. The roles of leptin and adiponectin: a novel paradigm in adipocytokine regulation of liver fibrosis and stellate cell biology. Am. J. Pathol. 166 (2005) 1655-1669
35. Dixon J.B., Bhathal P.S., Hughes N.R., and O'brien P.E. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology 39 (2004) 1647-1654
36. Dooley D., Hamzavi J., Breitkopf K., and Al E. Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats. Gastroenterology 125 (2003) 178-191
37. Dooley S., Delvoux B., Lahme B., Mangasser-Stephan K., and Gressner A.M. Modulation of transforming growth factor beta response and signaling during transdifferentiation of rat hepatic stellate cells to myofibroblasts. Hepatology 31 (2000) 1094-1106
38. Druker B.J., Sawyers C.L., Kantarjian H., Resta D.J., Reese S.F., Ford J.M., Capdeville R., and Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344 (2001) 1038-1042
39. Fallowfield J.A., and Iredale J.P. Reversal of liver fibrosis and cirrhosis-an emerging reality. Scott. Med. J. 49 (2004) 3-6
40. Fallowfield J.A., and Iredale J.P. Targeted treatments for cirrhosis. Expert. Opin. Ther. Targets 8 (2004) 423-435
41. Fauci A.S., Mavilio D., and Kottilil S. NK cells in HIV infection: paradigm for protection or targets for ambush. Nat. Rev. Immunol. 5 (2005) 835-843
42. Ferenci P., Dragosics B., Dittrich H., Frank H., Benda L., Lochs H., Meryn S., Base W., and Schneider B. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J. Hepatol. 9 (1989) 105-110
43. Fibbi G., Pucci M., Grappone C., Pellegrini G., Salzano R., Casini A., Milani S., and Del Rosso M. Functions of the fibrinolytic system in human Ito cells and its control by basic fibroblast and platelet-derived growth factor. Hepatology 29 (1999) 868-878
44. Fiorucci S., Antonelli E., Distrutti E., Severino B., Fiorentina R., Baldoni M., Caliendo G., Santagada V., Morelli A., and Cirino G. PAR1 antagonism protects against experimental liver fibrosis. Role of proteinase receptors in stellate cell activation. Hepatology 39 (2004) 365-375
45. Fiorucci S., Antonelli E., and Morelli A. Nitric oxide and portal hypertension: a nitric oxide-releasing derivative of ursodeoxycholic acid that selectively releases nitric oxide in the liver. Dig. Liver Dis. 35 Suppl. (2003) 61-69
46. Fiorucci S., Antonelli E., Morelli O., and Al E. NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension. PNAS 98 (2001) 8897-8902
47. Fiorucci S., Antonelli E., Rizzo G., Renga B., Mencarelli A., Riccardi L., Orlandi S., Pellicciari R., and Morelli A. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 127 (2004) 1497-1512
48. Fischer R., Cariers A., Reinehr R., and Haussinger D. Caspase 9-dependent killing of hepatic stellate cells by activated Kupffer cells. Gastroenterology 123 (2002) 845-861
49. Forbes S.J., Russo F.P., Rey V., Burra P., Rugge M., Wright N.A., and Alison M.R. A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. Gastroenterology 126 (2004) 955-963
50. Friedman S.L. Liver fibrosis-from bench to bedside. J. Hepatol. 38 Suppl. 1 (2003) S38-53
51. Friedman S.L. Mechanisms of hepatic fibrosis and therapeutic implications. Nat. Clin. Pract. Gastroenterol. Hepatol. 1 (2004) 98-105
52. Friedman S.L., and Arthur M.J. Reversing hepatic fibrosis. Sci. Med. 8 (2002) 194-205
53. Friedman S.L., and Bansal M.B. Reversal of hepatic fibrosis - fact or fantasy?. Hepatology 43 (2006) S82-S88
54. Friedman S.L., Wei S., and Blaner W.S. Retinol release by activated rat hepatic lipocytes: regulation by Kupffer cell-conditioned medium and PDGF. Am. J. Physiol. 264 (1993) G947-G952
55. Gaca M.D., Zhou X., Issa R., Kiriella K., Iredale J.P., and Benyon R.C. Basement membrane-like matrix inhibits proliferation and collagen synthesis by activated rat hepatic stellate cells: evidence for matrix-dependent deactivation of stellate cells. Matrix Biol. 22 (2003) 229-239
56. Galli A., Crabb D.W., Ceni E., Salzano R., Mello T., Svegliati-Baroni G., Ridolfi F., Trozzi L., Surrenti C., and Casini A. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 122 (2002) 1924-1940
57. Gao R., and Brigstock D.R. Connective tissue growth factor (CCN2) induces adhesion of rat activated hepatic stellate cells by binding of its C-terminal domain to integrin alpha(v)beta(3) and heparan sulfate proteoglycan. J. Biol. Chem. 279 (2004) 8848-8855
58. Garcia-Trevijano E.R., Iraburu M.J., Fontana L., Dominguez-Rosales J.A., Auster A., Covarrubias-Pinedo A., and Rojkind M. Transforming growth factor beta1 induces the expression of alpha1(I) procollagen mRNA by a hydrogen peroxide-C/EBPbeta-dependent mechanism in rat hepatic stellate cells. Hepatology 29 (1999) 960-970
59. George J., Roulot D., Koteliansky V.E., and Bissell D.M. In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. Proc. Natl. Acad. Sci. U S A 96 (1999) 12719-12724
60. George J., Wang S.S., Sevcsik A.M., Sanicola M., Cate R.L., Koteliansky V.E., and Bissell D.M. Transforming growth factor-beta initiates wound repair in rat liver through induction of the EIIIA-fibronectin splice isoform. Am. J. Pathol. 156 (2000) 115-124
61. Gressner A.M., Weiskirchen R., Breitkopf K., and Dooley S. Roles of tgf-beta in hepatic fibrosis. Front. Biosci. 7 (2002) D793-807
62. Grotendorst G.R. Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts. Cytokine Growth Factor Rev. 8 (1997) 171-179
63. Han Y.P. Matrix metalloproteinases, the pros and cons, in liver fibrosis. J. Gastroenterol. Hepatol. 21 Suppl. 3 (2006) S88-S91
64. Han Y.P., Yan C., Zhou L., Qin L., and Tsukamoto H. A matrix metalloproteinase-9 activation cascade by hepatic stellate cells in trans-differentiation in the three-dimensional extracellular matrix. J. Biol. Chem. 282 (2007) 12928-12939
65. Hashmi A.Z., Hakim W., Kruglov E.A., Watanabe A., Watkins W., Dranoff J.A., and Mehal W.Z. Adenosine inhibits cytosolic calcium signals and chemotaxis in hepatic stellate cells. Am. J. Physiol. Gastrointest. Liver Physiol. 292 (2007) G395-401
66. Haughton E.L., Tucker S.J., Marek C.J., Durward E., Leel V., Bascal Z., Monaghan T., Koruth M., Collie-Duguid E., Mann D.A., Trim J.E., and Wright M.C. Pregnane x receptor activators inhibit human hepatic stellate cell transdifferentiation in vitro. Gastroenterology 131 (2006) 194-209
67. Huang H., Shiffman M.L., Friedman S., Venkatesh R., Bzowej N., Abar O.T., Rowland C.M., Catanese J.J., Leong D.U., Sninsky J.J., Layden T.J., Wright T.L., White T., and Cheung R.C. A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology 46 (2007) 297-306
68. Hudnall S.D. Cyclosporin A renders target cells resistant to immune cytolysis. Eur. J. Immunol. 21 (1991) 221-226
69. Iimuro Y., Nishio T., Morimoto T., Nitta T., Stefanovic B., Choi S.K., Brenner D.A., and Yamaoka Y. Delivery of matrix metalloproteinase-1 attenuates established liver fibrosis in the rat. Gastroenterology 124 (2003) 445-458
70. Ikeda K., Wakahara T., Wang Y.Q., Kadoya H., Kawada N., and Kaneda K. In vitro migratory potential of rat quiescent hepatic stellate cells and its augmentation by cell activation. Hepatology 29 (1999) 1760-1767
71. Ikejima K., Honda H., Yoshikawa M., Hirose M., Kitamura T., Takei Y., and Sato N. Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals. Hepatology 34 (2001) 288-297
72. Imai S., Okuno M., Moriwaki H., Muto Y., Murakami K., Shudo K., Suzuki Y., and Kojima S. 9,13-di-cis-Retinoic acid induces the production of tPA and activation of latent TGF-beta via RAR alpha in a human liver stellate cell line, LI90. FEBS Lett. 411 (1997) 102-106
73. Inagaki Y., Nemoto T., Kushida M., Sheng Y., Higashi K., Ikeda K., Kawada N., Shirasaki F., Takehara K., Sugiyama K., Fujii M., Yamauchi H., Nakao A., De Crombrugghe B., Watanabe T., and Okazaki I. Interferon alfa down-regulates collagen gene transcription and suppresses experimental hepatic fibrosis in mice. Hepatology 38 (2003) 890-899
74. Inagaki Y., and Okazaki I. Emerging insights into Transforming growth factor beta Smad signal in hepatic fibrogenesis. Gut 56 (2007) 284-292
75. Iredale J.P. Hepatic stellate cell behavior during resolution of liver injury. Semin. Liver Dis. 21 (2001) 427-436
76. Iredale J.P., Benyon R.C., Pickering J., Mccullen M., Northrop M., Pawley S., Hovell C., and Arthur M.J. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J. Clin. Invest. 102 (1998) 538-549
77. Issa R., Williams E., Trim N., Kendall T., Arthur M.J., Reichen J., Benyon R.C., and Iredale J.P. Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors. Gut 48 (2001) 548-557
78. Issa R., Zhou X., Trim N., Millward-Sadler H., Krane S., Benyon C., and Iredale J. Mutation in collagen-1 that confers resistance to the action of collagenase results in failure of recovery from CCl4-induced liver fibrosis, persistence of activated hepatic stellate cells, and diminished hepatocyte regeneration. FASEB J. 17 (2003) 47-49
79. Iwamoto H., Sakai H., Kotoh K., Nakamuta M., and Nawata H. Soluble Arg-Gly-Asp peptides reduce collagen accumulation in cultured rat hepatic stellate cells. Dig. Dis. Sci. 44 (1999) 1038-1045
80. Jarnagin W.R., Rockey D.C., Koteliansky V.E., Wang S.S., and Bissell D.M. Expression of variant fibronectins in wound healing: cellular source and biological activity of the EIIIA segment in rat hepatic fibrogenesis. J. Cell Biol. 127 (1994) 2037-2048
81. Kalluri R., and Neilson E.G. Epithelial-mesenchymal transition and its implications for fibrosis. J. Clin. Invest. 112 (2003) 1776-1784
82. Kamada Y., Tamura S., Kiso S., Matsumoto H., Saji Y., Yoshida Y., Fukui K., Maeda N., Nishizawa H., Nagaretani H., Okamoto Y., Kihara S., Miyagawa J., Shinomura Y., Funahashi T., and Matsuzawa Y. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 125 (2003) 1796-1807
83. Kawada N., Seki S., Inoue M., and Kuroki T. Effect of antioxidants, resveratrol, quercetin, and N-acetylcysteine, on the functions of cultured rat hepatic stellate cells and Kupffer cells. Hepatology 27 (1998) 1265-1274
84. Kershenobich D., Vargas F., Garcia-Tsao G., Perez Tamayo R., Gent M., and Rojkind M. Colchicine in the treatment of cirrhosis of the liver. N. Engl. J. Med. 318 (1988) 1709-1713
85. Kim W.H., Matsumoto K., Bessho K., and Nakamura T. Growth inhibition and apoptosis in liver myofibroblasts promoted by hepatocyte growth factor leads to resolution from liver cirrhosis. Am. J. Pathol. 166 (2005) 1017-1028
86. Kinnman N., and Housset C. Peribiliary myofibroblasts in biliary type liver fibrosis. Front. Biosci. 7 (2002) D496-503
87. Kinnman N., Hultcrantz R., Barbu V., Rey C., Wendum D., Poupon R., and Housset C. PDGF-mediated chemoattraction of hepatic stellate cells by bile duct segments in cholestatic liver injury. Lab. Invest. 80 (2000) 697-707
88. Klein S., Mittendorfer B., Eagon J.C., Patterson B., Grant L., Feirt N., Seki E., Brenner D., Korenblat K., and Mccrea J. Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. Gastroenterology 130 (2006) 1564-1572
89. Knittel T., Fellmer P., and Ramadori G. Gene expression and regulation of plasminogen activator inhibitor type I in hepatic stellate cells of rat liver. Gastroenterology 111 (1996) 745-754
90. Kruglov E.A., Jain D., and Dranoff J.A. Isolation of primary rat liver fibroblasts. J. Invest. Med. 50 (2002) 179-184
91. Kurikawa N., Suga M., Kuroda S., Yamada K., and Ishikawa H. An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, improves experimental liver fibrosis by suppression of proliferation and collagen synthesis in activated hepatic stellate cells. Br. J. Pharmacol. 139 (2003) 1085-1094
92. Lechuga C.G., Hernandez-Nazara Z.H., Hernandez E., Bustamante M., Desierto G., Cotty A., Dharker N., Choe M., and Rojkind M. PI3K is involved in PDGF-beta receptor upregulation post-PDGF-BB treatment in mouse HSC. Am. J. Physiol. Gastrointest. Liver Physiol. 291 (2006) G1051-G1061
93. Leyland H., Gentry J., Arthur M.J., and Benyon R.C. The plasminogen-activating system in hepatic stellate cells. Hepatology 24 (1996) 1172-1178
94. Lindquist J.N., Parsons C.J., Stefanovic B., and Brenner D.A. Regulation of alpha1(I) collagen messenger RNA decay by interactions with alphaCP at the 3′-untranslated region. J. Biol. Chem. 279 (2004) 23822-23829
95. Liu C., Gaca M.D., Swenson E.S., Vellucci V.F., Reiss M., and Wells R.G. Smads 2 and 3 are differentially activated by transforming growth factor-beta (TGF-beta) in quiescent and activated hepatic stellate cells. Constitutive nuclear localization of Smads in activated cells is TGF-beta-independent. J. Biol. Chem. 278 (2003) 11721-11728
96. Maher J.J. Interactions between hepatic stellate cells and the immune system. Semin. Liver Dis. 21 (2001) 417-426
97. Marek C.J., Tucker S.J., Konstantinou D.K., Elrick L.J., Haefner D., Sigalas C., Murray G.I., Goodwin B., and Wright M.C. Pregnenolone-16alpha-carbonitrile inhibits rodent liver fibrogenesis via PXR (pregnane X receptor)-dependent and PXR-independent mechanisms. Biochem. J. 387 (2005) 601-608
98. Marra F. Chemokines in liver inflammation and fibrosis. Front. Biosci. 7 (2002) d1899-d1914
99. Marra F., Defranco R., Grappone C., Milani S., Pinzani M., Pellegrini G., Laffi G., and Gentilini P. Expression of the thrombin receptor in human liver: up-regulation during acute and chronic injury. Hepatology 27 (1998) 462-471
100. Marra F., Efsen E., Romanelli R.G., Caligiuri A., Pastacaldi S., Batignani G., Bonacchi A., Caporale R., Laffi G., Pinzani M., and Gentilini P. Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 119 (2000) 466-478
101. Marra F., Grandaliano G., Valente A.J., and Abboud H.E. Thrombin stimulates proliferation of liver fat-storing cells and expression of monocyte chemotactic protein-1: potential role in liver injury. Hepatology 22 (1995) 780-787
102. Marra F., Romanelli R.G., Giannini C., Failli P., Pastacaldi S., Arrighi M.C., Pinzani M., Laffi G., Montalto P., and Gentilini P. Monocyte chemotactic protein-1 as a chemoattractant for human hepatic stellate cells. Hepatology 29 (1999) 140-148
103. Martino V.D., Lebray P., Myers R.P., Pannier E., Paradis V., Charlotte F., Moussalli J., Thabut D., Buffet C., and Poynard T. Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure. Hepatology 40 (2004) 1426-1433
104. Masunaga H., Fujise N., Shiota A., Ogawa H., Sato Y., Imai E., Yasuda H., and Higashio K. Preventive effects of the deleted form of hepatocyte growth factor against various liver injuries. Eur. J. Pharmacol. 342 (1998) 267-279
105. Melhem A., Muhanna N., Bishara A., Alvarez C.E., Ilan Y., Bishara T., Horani A., Nassar M., Friedman S.L., and Safadi R. Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC. J. Hepatol. 45 (2006) 60-71
106. Melton A.C., Datta A., and Yee Jr. H.F. [Ca2+]i-independent contractile force generation by rat hepatic stellate cells in response to endothelin-1. Am. J. Physiol. Gastrointest. Liver Physiol. 290 (2006) G7-13
107. Melton A.C., and Yee H.F. Hepatic stellate cell protrusions couple platelet-derived growth factor-BB to chemotaxis. Hepatology 45 (2007) 1446-1453
108. Milani S., Herbst H., Schuppan D., Grappone C., Pellegrini G., Pinzani M., Casini A., Calabro A., Ciancio G., Stefanini F., et al. Differential expression of matrix-metalloproteinase-1 and -2 genes in normal and fibrotic human liver. Am. J. Pathol. 144 (1994) 528-537
109. Moreno M.G., and Muriel P. Remission of liver fibrosis by interferon-alpha 2b. Biochem. Pharmacol. 50 (1995) 515-520
110. Morishima C., Paschal D.M., Wang C.C., Yoshihara C.S., Wood B.L., Yeo A.E., Emerson S.S., Shuhart M.C., and Gretch D.R. Decreased NK cell frequency in chronic hepatitis C does not affect ex vivo cytolytic killing. Hepatology 43 (2006) 573-580
111. Murphy F.R., Issa R., Zhou X., Ratnarajah S., Nagase H., Arthur M.J., Benyon C., and Iredale J.P. Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. J. Biol. Chem. 277 (2002) 11069-11076
112. Nagula S., Jain D., Groszmann R.J., and Garcia-Tsao G. Histological-hemodynamic correlation in cirrhosis-a histological classification of the severity of cirrhosis. J. Hepatol. 44 (2006) 111-117
113. Napoli J., Bishop G.A., Mcguinness P.H., Painter D.M., and Mccaughan G.W. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology 24 (1996) 759-765
114. Niiya M., Uemura M., Zheng X.W., Pollak E.S., Dockal M., Scheiflinger F., Wells R.G., and Zheng X.L. Increased ADAMTS-13 proteolytic activity in rat hepatic stellate cells upon activation in vitro and in vivo. J. Thromb. Haemost. 4 (2006) 1063-1070
115. Novo E., Marra F., Zamara E., Valfre Di Bonzo L., Caligiuri A., Cannito S., Antonaci C., Colombatto S., Pinzani M., and Parola M. Dose dependent and divergent effects of superoxide anion on cell death, proliferation, and migration of activated human hepatic stellate cells. Gut 55 (2006) 90-97
116. Oakley F., Meso M., Iredale J.P., Green K., Marek C.J., Zhou X., May M.J., Millward-Sadler H., Wright M.C., and Mann D.A. Inhibition of inhibitor of kappaB kinases stimulates hepatic stellate cell apoptosis and accelerated recovery from rat liver fibrosis. Gastroenterology 128 (2005) 108-120
117. Oakley F., Trim N., Constandinou C.M., Ye W., Gray A.M., Frantz G., Hillan K., Kendall T., Benyon R.C., Mann D.A., and Iredale J.P. Hepatocytes express nerve growth factor during liver injury: evidence for paracrine regulation of hepatic stellate cell apoptosis. Am. J. Pathol. 163 (2003) 1849-1858
118. Okuno M., Akita K., Moriwaki H., Kawada N., Ikeda K., Kaneda K., Suzuki Y., and Kojima S. Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-beta. Gastroenterology 120 (2001) 1784-1800
119. Olaso E., Eng F., Lin C., Yancopoulous G., and Friedman S.L. The discoidin domain receptor 2 (DDR2) is induced during stellate cell activation, mediates cell growth and MMP2 expression, and is regulated by extracellular matrix. Hepatology 30 (1999) 413A
120. Omary M.B., Lugea A., Lowe A.W., and Pandol S.J. The pancreatic stellate cell: a star on the rise in pancreatic diseases. J. Clin. Invest. 117 (2007) 50-59
121. Paradis V., Perlemuter G., Bonvoust F., Dargere D., Parfait B., Vidaud M., Conti M., Huet S., Ba N., Buffet C., and Bedossa P. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 34 (2001) 738-744
122. Pares A., and Rodes J. Natural history of primary biliary cirrhosis. Clin. Liver Dis. 7 (2003) 779-794
123. Parsons C.J., Bradford B.U., Pan C.Q., Cheung E., Schauer M., Knorr A., Krebs B., Kraft S., Zahn S., Brocks B., Feirt N., Mei B., Cho M.S., Ramamoorthi R., Roldan G., Ng P., Lum P., Hirth-Dietrich C., Tomkinson A., and Brenner D.A. Antifibrotic effects of a tissue inhibitor of metalloproteinase-1 antibody on established liver fibrosis in rats. Hepatology 40 (2004) 1106-1115
124. Pietrangelo A., Borella F., Casalgrandi G., Montosi G., Ceccarelli D., Gallesi D., Giovannini F., Gasparetto A., and Masini A. Antioxidant activity of silybin in vivo during long-term iron overload in rats. Gastroenterology 109 (1995) 1941-1949
125. Pinzani M. PDGF and signal transduction in hepatic stellate cells. Front. Biosci. 7 (2002) d1720-d1726
126. Pinzani M., Failli P., Ruocco C., Casini A., Milani S., Baldi E., Giotti A., and Gentilini P. Fat-storing cells as liver-specific pericytes. Spatial dynamics of agonist-stimulated intracellular calcium transients. J. Clin. Invest. 90 (1992) 642-646
127. Pinzani M., and Marra F. Cytokine receptors and signaling in hepatic stellate cells. Semin. Liver Dis. 21 (2001) 397-416
128. Poynard T., Mathurin P., Lai C.L., Guyader D., Poupon R., Tainturier M.H., Myers R.P., Muntenau M., Ratziu V., Manns M., Vogel A., Capron F., Chedid A., and Bedossa P. A comparison of fibrosis progression in chronic liver diseases. J. Hepatol. 38 (2003) 257-265
129. Poynard T., Mchutchison J., Manns M., Trepo C., Lindsay K., Goodman Z., Ling M.H., and Albrecht J. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122 (2002) 1303-1313
130. Poynard T., Ratziu V., Charlotte F., Goodman Z., Mchutchison J., and Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. J. Hepatol. 34 (2001) 730-739
131. Preaux A.M., Mallat A., Rosenbaum J., Zafrani E.S., and Mavier P. Pentoxifylline inhibits growth and collagen synthesis of cultured human hepatic myofibroblast-like cells. Hepatology 26 (1997) 315-322
132. Rachfal A.W., and Brigstock D.R. Connective tissue growth factor (CTGF/CCN2) in hepatic fibrosis. Hepatol. Res. 26 (2003) 1-9
133. Radaeva S., Sun R., Jaruga B., Nguyen V.T., Tian Z., and Gao B. Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology 130 (2006) 435-452
134. Raetsch C., Jia J.D., Boigk G., Bauer M., Hahn E.G., Riecken E.O., and Schuppan D. Pentoxifylline downregulates profibrogenic cytokines and procollagen I expression in rat secondary biliary fibrosis. Gut 50 (2002) 241-247
135. Ramadori G., Veit T., Schwogler S., Dienes H.P., Knittel T., Rieder H., and Meyer Zum Buschenfelde K.H. Expression of the gene of the alpha-smooth muscle-actin isoform in rat liver and in rat fat-storing (ITO) cells. Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 59 (1990) 349-357
136. Ramalho L.N., Ramalho F.S., Zucoloto S., Castro-E-Silva Junior O., Correa F.M., Elias Junior J., and Magalhaes J.F. Effect of losartan, an angiotensin II antagonist, on secondary biliary cirrhosis. Hepatogastroenterology 49 (2002) 1499-1502
137. Reynaert H., Thompson M.G., Thomas T., and Geerts A. Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension. Gut 50 (2002) 571-581
138. Rippe R.A. Role of transcriptional factors in stellate cell activation. Alcohol. Clin. Exp. Res. 23 (1999) 926-929
139. Rockey D.C. Cellular pathophysiology of portal hypertension and prospects for management with gene therapy. Clin. Liver Dis. 5 (2001) 851-865
140. Rockey D.C. Hepatic blood flow regulation by stellate cells in normal and injured liver. Semin. Liver Dis. 21 (2001) 337-350
141. Rockey D.C. Vascular mediators in the injured liver. Hepatology 37 (2003) 4-12
142. Rockey D.C. Antifibrotic therapy in chronic liver disease. Clin. Gastroenterol. Hepatol. 3 (2005) 95-107
143. Rockey D.C., Boyles J.K., Gabbiani G., and Friedman S.L. Rat hepatic lipocytes express smooth muscle actin upon activation in vivo and in culture. J. Submicrosc. Cytol. Pathol. 24 (1992) 193-203
144. Rockey D.C., and Chung J.J. Interferon gamma inhibits lipocyte activation and extracellular matrix mRNA expression during experimental liver injury: implications for treatment of hepatic fibrosis. J. Invest. Med. 42 (1994) 660-670
145. Rockey D.C., and Chung J.J. Endothelin antagonism in experimental hepatic fibrosis. Implications for endothelin in the pathogenesis of wound healing. J. Clin. Invest. 98 (1996) 1381-1388
146. Rombouts K., Kisanga E., Hellemans K., Wielant A., Schuppan D., and Geerts A. Effect of HMG-CoA reductase inhibitors on proliferation and protein synthesis by rat hepatic stellate cells. J. Hepatol. 38 (2003) 564-572
147. Rombouts K., Knittel T., Machesky L., Braet F., Wielant A., Hellemans K., De Bleser P., Gelman I., Ramadori G., and Geerts A. Actin filament formation, reorganization and migration are impaired in hepatic stellate cells under influence of trichostatin A, a histone deacetylase inhibitor. J. Hepatol. 37 (2002) 788-796
148. Ruddell R.G., Oakley F., Hussain Z., Yeung I., Bryan-Lluka L.J., Ramm G.A., and Mann D.A. A role for serotonin (5-HT) in hepatic stellate cell function and liver fibrosis. Am. J. Pathol. 169 (2006) 861-876
149. Sanz S., Pucilowska J.B., Liu S., Rodriguez-Ortigosa C.M., Lund P.K., Brenner D.A., Fuller C.R., Simmons J.G., Pardo A., Martinez-Chantar M.L., Fagin J.A., and Prieto J. Expression of insulin-like growth factor I by activated hepatic stellate cells reduces fibrogenesis and enhances regeneration after liver injury. Gut 54 (2005) 134-141
150. Sato Y., Murase K., Kato J., Kobune M., Sato T., Kawano Y., Takimoto R., Takada K., Miyanishi K., Matsunaga T., Takayama T., and Niitsu Y. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat. Biotechnol. 26 (2008) 431-442
151. Saxena N.K., Ikeda K., Rockey D.C., Friedman S.L., and Anania F.A. Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology 35 (2002) 762-771
152. Saxena N.K., Titus M.A., Ding X., Floyd J., Srinivasan S., Sitaraman S.V., and Anania F.A. Leptin as a novel profibrogenic cytokine in hepatic stellate cells: mitogenesis and inhibition of apoptosis mediated by extracellular regulated kinase (Erk) and Akt phosphorylation. FASEB J. 18 (2004) 1612-1614
153. Schaefer B., Rivas-Estilla A.M., Meraz-Cruz N., Reyes-Romero M.A., Hernandez-Nazara Z.H., Dominguez-Rosales J.A., Schuppan D., Greenwel P., and Rojkind M. Reciprocal modulation of matrix metalloproteinase-13 and type I collagen genes in rat hepatic stellate cells. Am. J. Pathol. 162 (2003) 1771-1780
154. Schuetz E.G., Strom S., Yasuda K., Lecureur V., Assem M., Brimer C., Lamba J., Kim R.B., Ramachandran V., Komoroski B.J., Venkataramanan R., Cai H., Sinal C.J., Gonzalez F.J., and Schuetz J.D. Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. J. Biol. Chem. 276 (2001) 39411-39418
155. Shi Z., Wakil A.E., and Rockey D.C. Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses. Proc. Natl. Acad. Sci. U S A 94 (1997) 10663-10668
156. Shimizu E., Kobayashi Y., Oki Y., Kawasaki T., Yoshimi T., and Nakamura H. OPC-13013, a cyclic nucleotide phosphodiesterase type III, inhibitor, inhibits cell proliferation and transdifferentiation of cultured rat hepatic stellate cells. Life Sci. 64 (1999) 2081-2088
157. Shiratori Y., Imazeki F., Moriyama M., Yano M., Arakawa Y., Yokosuka O., Kuroki T., Nishiguchi S., Sata M., Yamada G., Fujiyama S., Yoshida H., and Omata M. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann. Intern. Med. 132 (2000) 517-524
158. Siller-Lopez F., Sandoval A., Salgado S., Salazar A., Bueno M., Garcia J., Vera J., Galvez J., Hernandez I., Ramos M., Aguilar-Cordova E., and Armendariz-Borunda J. Treatment with human metalloproteinase-8 gene delivery ameliorates experimental rat liver cirrhosis. Gastroenterology 126 (2004) 1122-1133 discussion 949
159. Stefanovic B., Schnabl B., and Brenner D.A. Inhibition of collagen a1(I) expression by the 5′ stem-loop as a molecular decoy. J. Biol. Chem. 11 (2002) 11
160. Stefanovic B., Stefanovic L., Schnabl B., Bataller R., and Brenner D.A. TRAM2 protein interacts with endoplasmic reticulum Ca2+ pump Serca2b and is necessary for collagen type I synthesis. Mol. Cell Biol. 24 (2004) 1758-1768
161. Stefanovic L., Stephens C.E., Boykin D., and Stefanovic B. Inhibitory effect of dicationic diphenylfurans on production of type I collagen by human fibroblasts and activated hepatic stellate cells. Life Sci. 76 (2005) 2011-2026
162. Steiling H., Muhlbauer M., Bataille F., Scholmerich J., Werner S., and Hellerbrand C. Activated hepatic stellate cells express keratinocyte growth factor in chronic liver disease. Am. J. Pathol. 165 (2004) 1233-1241
163. Svegliati Baroni G., D'ambrosio L., Ferretti G., Casini A., Di Sario A., Salzano R., Ridolfi F., Saccomanno S., Jezequel A.M., and Benedetti A. Fibrogenic effect of oxidative stress on rat hepatic stellate cells. Hepatology 27 (1998) 720-726
164. Tada S., Iwamoto H., Nakamuta M., Sugimoto R., Enjoji M., Nakashima Y., and Nawata H. A selective ROCK inhibitor, Y27632, prevents dimethylnitrosamine-induced hepatic fibrosis in rats. J. Hepatol. 34 (2001) 529-536
165. Tahashi Y., Matsuzaki K., Date M., Yoshida K., Furukawa F., Sugano Y., Matsushita M., Himeno Y., Inagaki Y., and Inoue K. Differential regulation of TGF-beta signal in hepatic stellate cells between acute and chronic rat liver injury. Hepatology 35 (2002) 49-61
166. Taimr P., Higuchi H., Kocova E., Rippe R.A., Friedman S., and Gores G.J. Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis. Hepatology 37 (2003) 87-95
167. Tasci I., Mas M.R., Vural S.A., Comert B., Alcigir G., Serdar M., Mas N., Isik A.T., and Ates Y. Rat liver fibrosis regresses better with pegylated interferon alpha2b and ursodeoxycholic acid treatments than spontaneous recovery. Liver Int. 26 (2006) 261-268
168. Theret N., Lehti K., Musso O., and Clement B. MMP2 activation by collagen I and concanavalin A in cultured human hepatic stellate cells. Hepatology 30 (1999) 462-468
169. Theret N., Musso O., L'helgoualc'h A., and Clement B. Activation of matrix metalloproteinase-2 from hepatic stellate cells requires interactions with hepatocytes. Am. J. Pathol. 150 (1997) 51-58
170. Trotter J.F. Sirolimus in liver transplantation. Transplant. Proc. 35 (2003) 193S-200S
171. Tsukada S., Parsons C.J., and Rippe R.A. Mechanisms of liver fibrosis. Clin. Chim. Acta 364 (2006) 33-60
172. Ueki T., Kaneda Y., Tsutsui H., Nakanishi K., Sawa Y., Morishita R., Matsumoto K., Nakamura T., Takahashi H., Okamoto E., and Fujimoto J. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat. Med. 5 (1999) 226-230
173. Valentino K.L., Gutierrez M., Sanchez R., Winship M.J., and Shapiro D.A. First clinical trial of a novel caspase inhibitor: anti-apoptotic caspase inhibitor, IDN-6556, improves liver enzymes. Int. J. Clin. Pharmacol. Ther. 41 (2003) 441-449
174. Vyas S.K., Leyland H., Gentry J., and Arthur M.J. Rat hepatic lipocytes synthesize and secrete transin (stromelysin) in early primary culture. Gastroenterology 109 (1995) 889-898
175. Wahl S.M., Frazier-Jessen M., Jin W.W., Kopp J.B., Sher A., and Cheever A.W. Cytokine regulation of schistosome-induced granuloma and fibrosis. Kidney Int. 51 (1997) 1370-1375
176. Wells R.G., Kruglov E., and Dranoff J.A. Autocrine release of TGF-beta by portal fibroblasts regulates cell growth. FEBS Lett. 559 (2004) 107-110
177. Whalen R., Rockey D.C., Friedman S.L., and Boyer T.D. Activation of rat hepatic stellate cells leads to loss of glutathione S-transferases and their enzymatic activity against products of oxidative stress. Hepatology 30 (1999) 927-933
178. Wiedmann M.W., and Caca K. Molecularly targeted therapy for gastrointestinal cancer. Curr. Cancer Drug Targets 5 (2005) 171-193
179. Williams E.J., Benyon R.C., Trim N., Hadwin R., Grove B.H., Arthur M.J., Unemori E.N., and Iredale J.P. Relaxin inhibits effective collagen deposition by cultured hepatic stellate cells and decreases rat liver fibrosis in vivo. Gut 49 (2001) 577-583
180. Wong L., Yamasaki G., Johnson R.J., and Friedman S.L. Induction of beta-platelet-derived growth factor receptor in rat hepatic lipocytes during cellular activation in vivo and in culture. J. Clin. Invest. 94 (1994) 1563-1569
181. Wright M., Issa R., Smart D., and Al E. Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. Gastroenterology 121 (2001) 685-698
182. Yoshiji H., Kuriyama S., Yoshii J., Ikenaka Y., Noguchi R., Hicklin D.J., Wu Y., Yanase K., Namisaki T., Yamazaki M., Tsujinoue H., Imazu H., Masaki T., and Fukui H. Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis. Gut 52 (2003) 1347-1354
183. Yoshiji H., Kuriyama S., Yoshii J., Ikenaka Y., Noguchi R., Nakatani T., Tsujinoue H., Yanase K., Namisaki T., Imazu H., and Fukui H. Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse. Hepatology 36 (2002) 850-860
184. Yoshiji H., Noguchi R., Kuriyama S., Ikenaka Y., Yoshii J., Yanase K., Namisaki T., Kitade M., Masaki T., and Fukui H. Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats. Am. J. Physiol. Gastrointest. Liver Physiol. 288 (2005) G907-G913
185. Yu C., Wang F., Jin C., Huang X., Miller D.L., Basilico C., and Mckeehan W.L. Role of fibroblast growth factor type 1 and 2 in carbon tetrachloride-induced hepatic injury and fibrogenesis. Am. J. Pathol. 163 (2003) 1653-1662
186. Zhang L.P., Takahara T., Yata Y., Furui K., Jin B., Kawada N., and Watanabe A. Increased expression of plasminogen activator and plasminogen activator inhibitor during liver fibrogenesis of rats: role of stellate cells. J. Hepatol. 31 (1999) 703-711
187. Zhu J., Wu J., Frizell E., Liu S.L., Bashey R., Rubin R., Norton P., and Zern M.A. Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis. Gastroenterology 117 (1999) 1198-1204